CSTL
Castle Biosciences, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Buy
+41/100
Last price
33.36
▼ 3.29 (8.98%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
36.65
Prev close
36.65
Day high
37.99
Day low
33.10
Volume
609.14K
Market cap
$1.02B
P/E (TTM)
—
52W range
17.72 – 44.28
Day trading desk
Gap from prior close
0.00%
Prior close 36.65
VWAP
33.62
-0.77% from price
Relative volume
2.68×
Unusually busy
Session range
14.77%
33.10 – 37.99
Position in range
5%
Near session low
ATR (14D)
1.77
5.30% of price
Prior day high
36.76
PDH
Prior day low
35.10
PDL
Bid / ask spread
—
Quote not published
Session volume
1.07M
Avg 398.84K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-4.36%
-6.3%
1M
+1.37%
+0.2%
3M
+41.12%
+36.6%
6M
+34.35%
+16.2%
YTD
-14.24%
-28.5%
1Y
+46.83%
+30.4%
3Y
+97.51%
+15.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on CSTL open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-98.75K
Net selling
Buy transactions
25
219.19K shares
Sell transactions
29
317.94K shares
Net transactions
+54
Buys less sells
Sell : buy shares
1.5 : 1
Mixed
Insider-held shares
731.97K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Oct 1, 26 | OELSCHLAGER KRISTEN M Chief Operating Officer |
SELL | 4.15K | $149.32K | Direct |
| Oct 1, 26 | OELSCHLAGER KRISTEN M Chief Operating Officer |
CONVERSION | 4.15K | $14.04K | Direct |
| Sep 30, 26 | JUVENAL TOBIN W Officer |
SELL | 6.58K | $232.13K | Direct |
| Sep 21, 26 | MAETZOLD DEREK J Chief Executive Officer |
SELL | 14.50K | $512.20K | |
| Sep 21, 26 | MAETZOLD DEREK J Chief Executive Officer |
CONVERSION | 8.58K | $20.51K | Direct |
| Sep 15, 26 | JUVENAL TOBIN W Officer |
SELL | 6.60K | $222.62K | Direct |
| Sep 11, 26 | MAETZOLD DEREK J Chief Executive Officer |
SELL | 14.52K | $464.87K | |
| Sep 11, 26 | MAETZOLD DEREK J Chief Executive Officer |
CONVERSION | 8.58K | $20.52K | Direct |
| Sep 1, 26 | OELSCHLAGER KRISTEN M Chief Operating Officer |
SELL | 4.15K | $138.64K | Direct |
| Sep 1, 26 | OELSCHLAGER KRISTEN M Chief Operating Officer |
CONVERSION | 4.15K | $14.03K | Direct |
| Aug 31, 26 | JUVENAL TOBIN W Officer |
SELL | 1.73K | $56.76K | Direct |
| Aug 28, 26 | MAETZOLD DEREK J Chief Executive Officer |
SELL | 18.56K | $616.13K | |
| Aug 28, 26 | MAETZOLD DEREK J Chief Executive Officer |
CONVERSION | 12.43K | $29.70K | Direct |
| Aug 25, 26 | OELSCHLAGER KRISTEN M Chief Operating Officer |
SELL | 24.60K | $837.87K | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BRADBURY DANIEL M |
Director | 35.63K | Conversion of Exercise of derivative security |
CAPLE KIM |
Director | 36.12K | Conversion of Exercise of derivative security |
COTTON RODNEY |
Director | 33.00K | Conversion of Exercise of derivative security |
GOLDBERG ELLEN |
Director | 40.92K | Conversion of Exercise of derivative security |
HARRISON MILES D |
Director | 35.63K | Conversion of Exercise of derivative security |
JUVENAL TOBIN W |
Officer | 52.01K | Sale |
MAETZOLD DEREK J |
Chief Executive Officer | — | Sale |
OELSCHLAGER KRISTEN M |
Chief Operating Officer | 86.00K | Sale |
OLSON TIFFANY |
Director | 39.57K | Conversion of Exercise of derivative security |
STOKES FRANKLIN M. |
Chief Financial Officer | 35.18K | Sale |
Fundamentals
Market cap$1.02B
Enterprise value$788.98M
Revenue (TTM)$357.28M
Gross profit$276.03M
EBITDA$-16.52M
Net income$-19.41M
EPS (TTM)$-0.58
Free cash flow$-7.26M
Total cash$266.80M
Total debt$36.65M
Book value / share$15.41
Shares outstanding30.55M
Float27.15M
Short % of float6.37%
Dividend yield0.00%
Beta (5Y)0.95
Valuation & profitability ratios
Trailing P/E—
Forward P/E-35.53
PEG ratio—
Price / sales—
Price / book2.17
EV / revenue2.21
EV / EBITDA-47.77
Gross margin77.26%
Operating margin-2.96%
Profit margin-5.43%
Return on equity-4.20%
Return on assets-1.36%
Debt / equity7.80
Current ratio6.04
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $344.23M | $332.07M | $219.79M | $137.04M | +3.7% |
| Operating revenue | $344.23M | $332.07M | $219.79M | $137.04M | +3.7% |
| Cost of revenue | $71.03M | $60.20M | $44.98M | $32.01M | +18.0% |
| Gross profit | $273.20M | $271.86M | $174.81M | $105.03M | +0.5% |
| Research & development | $51.85M | $52.04M | $53.62M | $44.90M | -0.4% |
| Selling, general & admin | $229.32M | $200.05M | $180.15M | $143.00M | +14.6% |
| Total operating expense | $316.01M | $263.19M | $242.78M | $196.17M | +20.1% |
| Operating income | -$42.81M | $8.67M | -$67.98M | -$91.14M | -593.8% |
| Net interest income | $11.69M | $12.34M | $10.61M | $3.95M | -5.3% |
| Pre-tax income | -$29.51M | $21.56M | -$57.37M | -$68.90M | -236.9% |
| Tax provision | -$5.36M | $3.32M | $101.00K | -$1.77M | -261.4% |
| Net income | -$24.16M | $18.25M | -$57.47M | -$67.14M | -232.4% |
| Net income to common | -$24.16M | $18.25M | -$57.47M | -$67.14M | -232.4% |
| Basic EPS | -0.83 | 0.66 | -2.14 | -2.58 | -225.8% |
| Diluted EPS | -0.83 | 0.62 | -2.14 | -2.58 | -233.9% |
| EBIT | -$29.43M | $22.14M | -$57.35M | -$68.89M | -232.9% |
| EBITDA | $11.34M | $38.14M | -$45.02M | -$58.34M | -70.3% |
| Basic shares | 28.99M | 27.78M | 26.80M | 26.05M | +4.4% |
| Diluted shares | 28.99M | 29.25M | 26.80M | 26.05M | -0.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $116.73M | $119.71M | $98.84M | $122.95M | -2.5% |
| Cash & short-term investments | $299.50M | $293.13M | $243.10M | $258.63M | +2.2% |
| Accounts receivable | $43.38M | $51.22M | $38.30M | $23.48M | -15.3% |
| Inventory | $10.25M | $8.13M | $7.94M | $3.98M | +26.0% |
| Total current assets | $361.10M | $360.15M | $295.63M | $292.29M | +0.3% |
| Property, plant & equipment | $112.24M | $62.71M | $37.74M | $26.50M | +79.0% |
| Goodwill & intangibles | $99.57M | $106.23M | $117.33M | $126.35M | -6.3% |
| Total assets | $578.56M | $531.24M | $453.34M | $447.33M | +8.9% |
| Total current liabilities | $68.68M | $49.39M | $47.67M | $36.13M | +39.0% |
| Current debt | $417.00K | $278.00K | — | — | +50.0% |
| Long-term debt | $9.64M | $9.74M | — | — | -1.1% |
| Total debt | $36.91M | $26.34M | $15.34M | $13.40M | +40.1% |
| Total liabilities | $107.68M | $75.40M | $62.07M | $48.18M | +42.8% |
| Retained earnings | -$224.28M | -$200.13M | -$218.37M | -$160.91M | -12.1% |
| Shareholder equity | $470.87M | $455.83M | $391.27M | $399.15M | +3.3% |
| Working capital | $292.42M | $310.76M | $247.97M | $256.16M | -5.9% |
| Net tangible assets | $371.30M | $349.61M | $273.93M | $272.80M | +6.2% |
| Shares issued | 29.69M | 28.48M | 27.41M | 26.55M | +4.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$24.16M | $18.25M | -$57.47M | -$67.14M | -232.4% |
| Depreciation & amortisation | $40.77M | $16.00M | $12.33M | $10.54M | +154.9% |
| Stock-based compensation | $45.89M | $50.32M | $51.22M | $36.32M | -8.8% |
| Change in working capital | $13.60M | -$14.13M | -$6.63M | -$7.00K | +196.3% |
| Operating cash flow | $64.35M | $64.87M | -$5.63M | -$41.66M | -0.8% |
| Capital expenditure | -$36.02M | -$28.33M | -$13.62M | -$5.63M | -27.2% |
| Investing cash flow | -$60.37M | -$50.14M | -$16.18M | -$166.54M | -20.4% |
| Financing cash flow | -$6.96M | $6.14M | -$2.30M | $1.51M | -213.4% |
| Free cash flow | $28.33M | $36.54M | -$19.25M | -$47.29M | -22.5% |
| End cash position | $116.73M | $119.71M | $98.84M | $122.95M | -2.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $103.55M | $83.68M | $87.01M | $83.04M | $86.19M | +23.7% |
| Operating revenue | $103.55M | $83.68M | $87.01M | $83.04M | $86.19M | +23.7% |
| Cost of revenue | $23.70M | $20.53M | $18.32M | $18.70M | $17.63M | +15.4% |
| Gross profit | $79.85M | $63.15M | $68.69M | $64.34M | $68.56M | +26.4% |
| Research & development | $14.54M | $14.43M | $13.52M | $12.96M | $12.79M | +0.8% |
| Selling, general & admin | $66.12M | $64.90M | $56.73M | $55.91M | $58.06M | +1.9% |
| Total operating expense | $82.92M | $81.55M | $72.52M | $71.14M | $72.81M | +1.7% |
| Operating income | -$3.07M | -$18.41M | -$3.83M | -$6.80M | -$4.25M | +83.3% |
| Net interest income | $2.16M | $2.41M | $2.87M | $2.81M | $2.92M | -10.3% |
| Pre-tax income | -$1.69M | -$14.41M | -$2.71M | -$386.00K | -$143.00K | +88.3% |
| Tax provision | $370.00K | $109.00K | -$382.00K | $115.00K | -$4.67M | +239.4% |
| Net income | -$2.06M | -$14.52M | -$2.33M | -$501.00K | $4.52M | +85.8% |
| Net income to common | -$2.06M | -$14.52M | -$2.33M | -$501.00K | $4.52M | +85.8% |
| Basic EPS | -0.07 | -0.49 | -0.08 | -0.02 | 0.16 | +85.7% |
| Diluted EPS | -0.07 | -0.49 | -0.08 | -0.02 | 0.15 | +85.7% |
| EBIT | -$1.50M | -$14.28M | -$2.69M | -$362.00K | -$122.00K | +89.5% |
| EBITDA | $2.57M | -$10.35M | $1.09M | $3.45M | $3.29M | +124.9% |
| Basic shares | 30.40M | 29.89M | 29.33M | 29.07M | 28.91M | +1.7% |
| Diluted shares | 30.40M | 29.89M | 29.33M | 29.07M | 29.55M | +1.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $62.12M | $63.76M | $116.73M | $85.56M | $82.23M | — | -2.6% |
| Cash & short-term investments | $266.81M | $261.69M | $299.50M | $287.54M | $275.93M | — | +2.0% |
| Accounts receivable | $48.34M | $42.26M | $43.38M | $49.48M | $52.31M | — | +14.4% |
| Inventory | $10.58M | $10.46M | $10.25M | $8.65M | $8.37M | — | +1.1% |
| Total current assets | $341.10M | $328.90M | $361.10M | $357.57M | $348.67M | — | +3.7% |
| Property, plant & equipment | $118.88M | $115.36M | $112.24M | $100.04M | $89.56M | — | +3.1% |
| Goodwill & intangibles | $95.10M | $97.35M | $99.57M | $101.85M | $104.13M | — | -2.3% |
| Total assets | $561.18M | $547.80M | $578.56M | $562.79M | $544.73M | — | +2.4% |
| Total current liabilities | $56.51M | $48.76M | $68.68M | $55.31M | $50.89M | — | +15.9% |
| Current debt | $2.92M | $1.67M | $417.00K | — | $1.94M | $1.11M | +75.0% |
| Long-term debt | $7.16M | $8.40M | $9.64M | $10.05M | $8.10M | — | -14.8% |
| Total debt | $36.65M | $36.72M | $36.91M | $37.14M | $37.35M | — | -0.2% |
| Total liabilities | $91.15M | $86.39M | $107.68M | $95.74M | $89.35M | — | +5.5% |
| Retained earnings | -$240.87M | -$238.81M | -$224.28M | -$221.95M | -$221.45M | — | -0.9% |
| Shareholder equity | $470.03M | $461.42M | $470.87M | $467.05M | $455.38M | — | +1.9% |
| Working capital | $284.59M | $280.14M | $292.42M | $302.26M | $297.78M | — | +1.6% |
| Net tangible assets | $374.93M | $364.07M | $371.30M | $365.20M | $351.25M | — | +3.0% |
| Shares issued | 30.51M | 30.30M | 29.69M | 29.16M | 28.98M | — | +0.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$2.06M | -$14.52M | -$2.33M | -$501.00K | $4.52M | +85.8% |
| Depreciation & amortisation | $4.07M | $3.93M | $3.78M | $3.82M | $3.41M | +3.6% |
| Stock-based compensation | $11.59M | $9.78M | $11.41M | $12.10M | $11.21M | +18.5% |
| Change in working capital | $1.13M | -$19.36M | $13.97M | $11.50M | $8.51M | +105.8% |
| Operating cash flow | $15.20M | -$22.13M | $26.93M | $22.63M | $20.82M | +168.7% |
| Capital expenditure | -$8.65M | -$12.46M | -$7.18M | -$14.83M | -$9.26M | +30.5% |
| Investing cash flow | -$15.96M | -$25.80M | $8.83M | -$18.39M | -$28.38M | +38.1% |
| Financing cash flow | -$886.00K | -$5.03M | -$4.59M | -$919.00K | $101.00K | +82.4% |
| Free cash flow | $6.55M | -$34.58M | $19.75M | $7.80M | $11.56M | +118.9% |
| End cash position | $62.12M | $63.76M | $116.73M | $85.56M | $82.23M | -2.6% |
Options analytics
Put / call volume
0.47
Call-heavy session
Put / call open interest
0.13
Positioning, not flow
Max pain
20.00
-40.0% from spot
ATM implied vol
89.4%
Nearest strike to spot
Skew (10% OTM)
-18.1%
Calls bid over puts
Call volume
30
Contracts, this expiry
Put volume
14
Contracts, this expiry
Heaviest call OI
40.00
247 contracts
Heaviest put OI
20.00
24 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.41 | -0.07 | +82.8% |
| Mar 2026 | -0.49 | -0.49 | -0.3% |
| Dec 2025 | -0.26 | -0.08 | +69.1% |
| Sep 2025 | -0.51 | -0.02 | +96.1% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.35 | 9 | $92.36M | +11.2% |
| Next quarter | -0.36 | 9 | $94.01M | +8.0% |
| Current year | -1.27 | 9 | $373.17M | +8.4% |
| Next year | -0.94 | 9 | $411.62M | +10.3% |
Analyst targets & ownership
Mean target$45.11
High target$57.00
Low target$35.00
Implied upside35.23%
Analyst count9
ConsensusSTRONG BUY
Strong buy / Buy0 / 9
Hold0
Sell / Strong sell0 / 0
Held by insiders2.40%
Held by institutions91.01%
Institutions holding259
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
35.30
-5.51% from price
SMA 20
34.82
-4.19% from price
SMA 50
32.74
+1.89% from price
SMA 100
27.44
+21.58% from price
SMA 200
29.04
+14.86% from price
EMA 12
35.07
-4.88% from price
EMA 26
34.31
-2.76% from price
EMA 50
32.46
+2.78% from price
RSI (14)
45.8
Neutral
MACD (12,26,9)
0.77
Hist -0.25
ATR (14)
1.77
5.30% of price
Realised vol 30D
44.6%
Annualised
Bollinger upper
37.46
20, 2σ
Bollinger lower
32.18
20, 2σ
50 / 200 cross
Golden
32.74 vs 29.04
Trend bias
Above 200
+14.86%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.84
Less volatile than market
Correlation to SPY
0.19
Largely independent
Realised vol 30D
44.6%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-57.8%
Peak to trough
Max drawdown 5Y
-82.7%
Peak to trough
ATR 14
1.77
5.30% of price
Beta (reported)
0.95
5Y monthly, from filing
Short interest
Shares short
1.90M
Prior 1.75M
Change vs prior
+8.3%
Shorts adding
% of float
6.37%
Normal
% of shares out
6.22%
Against total outstanding
Days to cover
5.7
Crowded exit
Float
27.15M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 3, 26 | BTIG | MAINTAINED | Buy | Buy |
| Jun 25, 26 | Roth Capital | INITIATED | — | Buy |
| May 13, 26 | BTIG | MAINTAINED | Buy | Buy |
| May 7, 26 | Baird | MAINTAINED | Outperform | Outperform |
| Apr 20, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Feb 27, 26 | Baird | MAINTAINED | Outperform | Outperform |
| Jan 26, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Jan 12, 26 | Lake Street | MAINTAINED | Buy | Buy |
| Jan 5, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Dec 22, 25 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Dec 12, 25 | BTIG | MAINTAINED | Buy | Buy |
| Nov 5, 25 | BTIG | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Trading Registrations
8-A12B · 2026-08-14
Corporate Changes & Voting Matters
8-K · 2026-07-30
Corporate Changes & Voting Matters
8-K · 2026-05-29
Corporate Changes & Voting Matters
8-K · 2026-05-06
Proxy Statements
DEFA14A · 2026-04-08
Offering Registrations
S-8 · 2026-02-26
Corporate Changes & Voting Matters
8-K · 2026-01-13
Corporate Changes & Voting Matters
8-K · 2025-11-03
Headlines
Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management
PR Newswire · 6d ago
New Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus
PR Newswire · 9d ago
New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™
PR Newswire · 12d ago
Castle Biosciences to Open New Laboratory Facility in Scottsdale
PR Newswire · 15d ago
New Decision Modeling Study Demonstrates TissueCypher® Significantly Improves Risk-Aligned Management for Patients with Barrett's Esophagus
PR Newswire · 22d ago
JAAD Publication Shows Improved Performance of DecisionDx®-SCC
PR Newswire · 27d ago
Castle Biosciences, Inc. (CSTL) Is Up 15.46% in One Week: What You Should Know
Zacks · 39d ago
Castle Biosciences (CSTL) Rallies On Earnings Optimism, Is The Stock Still Cheap?
Simply Wall St. · 41d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.